Diagnosed with Bronchiectasis — Your Medical Aid Questions Answered

Bronchiectasis is a long-term condition that requires daily management, regular pulmonologist review, and prompt antibiotic treatment during exacerbations. This guide addresses the key questions about what your medical aid must cover and how to access it effectively.

Does My Medical Aid Have to Cover This?

Yes. Bronchiectasis is a CDL condition. Core maintenance medications — including long-term azithromycin, hypertonic saline, and bronchodilators — must be funded from the CDL benefit once registered. Acute exacerbations requiring hospitalisation and IV antibiotics are covered under PMB as emergency admissions.

Register for CDL as Soon as Possible

CDL registration is the step that unlocks your entitlement to ongoing medication funding from the chronic benefit rather than your medical savings account. Contact the scheme's chronic disease department and submit:

• Pulmonologist's letter confirming the diagnosis of bronchiectasis (ICD-10: J47)
• CT chest report documenting bronchiectatic changes — this is the gold-standard diagnostic confirmation; a chest X-ray alone is insufficient
• Lung function test results (spirometry) if available
• CDL registration form (obtainable from the scheme)

Once registered, maintenance medications are funded from the CDL benefit — not depleted from your MSA. For a condition requiring lifelong, ongoing treatment, this distinction is financially significant.

Daily Airway Clearance: Your Most Important Treatment

More important than any medication is consistent, daily airway clearance. Bronchiectasis accumulates secretions in the damaged airways — without active clearance, these secretions become infected and drive exacerbations. Chest physiotherapy and oscillating PEP devices (flutter valves, Aerobika, acapella) mechanically break up and mobilise secretions for expectoration.

Most plan physiotherapy benefits (10–20 sessions per year) were not designed for a condition requiring daily therapy. To navigate this:

• Ask your pulmonologist to write a CDL physiotherapy motivation — some schemes allow enhanced access for CDL conditions beyond the standard annual physiotherapy limit
• Enquire whether a pulmonary rehabilitation programme provides alternative physiotherapy access
• Consider purchasing a home-use airway clearance device (R2,000–R5,000 once-off) for independent daily use — this significantly reduces dependence on the scheme's physiotherapy benefit for routine maintenance

Most respiratory physiotherapists will teach airway clearance techniques and device use in 2–4 sessions; you can then maintain the routine independently.

Managing Exacerbations: The 24-Hour Rule

When your symptoms worsen — increased sputum volume, change in sputum colour to green or dark yellow, new breathlessness, fever, or chest pain — contact your pulmonologist within 24 hours. Early antibiotic treatment (guided by prior sputum culture results) is critical. Delayed treatment turns an outpatient antibiotic course into a hospital admission with IV antibiotics. That is better for neither your health nor your finances.

The scheme may require authorisation for extended antibiotic courses (beyond 7 days) or specific antibiotics like ciprofloxacin. Ask your pulmonologist's rooms to manage pre-authorisation, or call the scheme's chronic authorisation line in advance of filling the prescription.

Pseudomonas: When Things Get More Complex

Pseudomonas aeruginosa is a gram-negative bacterium that colonises damaged airways in advanced bronchiectasis. Confirmed colonisation (positive sputum cultures on two or more occasions, more than three months apart) is a significant clinical marker. Your pulmonologist will discuss inhaled antibiotic therapy — inhaled tobramycin (TOBI) or colistin — to suppress Pseudomonas and reduce the exacerbation rate.

Monthly cost for inhaled tobramycin: approximately R7,000–R10,000. These are expensive and not on standard CDL formularies — your pulmonologist must submit an exceptional-needs motivation. The motivation should include:

• Confirmed Pseudomonas colonisation with culture dates and sensitivities
• Exacerbation frequency per year
• Lung function trend (FEV1)
• ERS Bronchiectasis Guideline recommendation for inhaled antibiotics in Pseudomonas-positive bronchiectasis

The cost of one prevented IV antibiotic admission (R50,000–R120,000) substantially exceeds the annual cost of prophylactic inhaled antibiotics — this economic argument can and should be included in the motivation.

Confirming Your CDL Medications Are Correct

After CDL registration, the following should be funded from the CDL benefit (not MSA):

• Long-term azithromycin (if prescribed as prophylaxis)
• Hypertonic saline nebuliser solution (if prescribed)
• Bronchodilators (short-acting or long-acting, if prescribed for co-existing airflow obstruction)
• Scheme-approved inhaled antibiotic (if authorised for Pseudomonas)

If any of these are being charged to your savings account, submit a written reclassification request to the scheme with your CDL registration confirmation and prescription details.

Pulmonary Rehabilitation

Structured pulmonary rehabilitation — combining supervised exercise training, education, and physiotherapy — is evidence-based for moderate-to-severe bronchiectasis. It improves exercise capacity, reduces exacerbation frequency, and significantly improves quality of life. Ask your pulmonologist whether a formal pulmonary rehabilitation programme is available at your treating hospital and whether it can be accessed through the CDL management pathway.

Checklist

Support Resources

Lung Association of South Africa (LASA): www.lungsa.org.za Patient education, advocacy, and respiratory disease support.

Talk to Eldon

Get help understanding your plan options →

This page is general information about medical schemes. It is not medical advice: speak to a healthcare professional about your own treatment. Medical aid and gap cover advice is given by Eldon de Waal, a Supervised Representative of Approach Administration (FSP 23579).